2,3,5,21-Tetraphenylporphyrin--zinc (1/1) | 25447-11-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四吡咯及其衍生物
• 英文名称: 2,3,5,21-Tetraphenylporphyrin--zinc (1/1)
• 英文别名: 10,12,13,23-tetraphenyl-21H-porphyrin;zinc
• CAS: 25447-11-4
• 化学式: C44H30N4Zn
• 分子量: 680.1
• InChiKey: NCTCAYZLKLJIQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.12
• 重原子数：
  49
• 可旋转键数：
  4
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• METHODS OF SYNTHESIZING LABELED NUCLEOSIDES
  申请人：Singular Genomics Systems, Inc.

  公开号：US20190077726A1

  公开（公告）日：2019-03-14

  Disclosed herein, inter alia, are compounds, compositions, and methods of synthesizing labeled nucleosides.

  在此披露的内容包括化合物、组合物和合成标记核苷的方法。
• [EN] BETA-SUBSTITUTED PORPHYRINS<br/>[FR] PORPHYRINES A SUBSTITUTION BETA
  申请人：UNIV MASSEY

  公开号：WO2006038823A1

  公开（公告）日：2006-04-13

  The invention relates to ÿ-substituted porphyrins, methods for their synthesis, and their use in the preparation of photoelectric materials. In particular, the invention relates to solid state photoelectric devices, including solar cells and photodetectors, incorporating these photoelectric materials, with improved photon-to-current conversion efficiencies.

  这项发明涉及ÿ-取代卟啉，其合成方法，以及它们在制备光电材料中的应用。具体而言，该发明涉及固态光电器件，包括太阳能电池和光电探测器，这些器件包含这些光电材料，具有改善的光子到电流转换效率。
• DIBENZOFLUORANTHENE COMPOUND AND ORGANIC THIN-FILM SOLAR CELL USING SAME
  申请人：Ikeda Hidetsugu

  公开号：US20120298203A1

  公开（公告）日：2012-11-29

  A dibenzofluoranthene compound represented by the following formula (A). In the formula at least one of R 1 to R 14 is an amino group represented by the following formula (S); R 1 to R 14 that is not an amino group represented by the formula (S) are independently a hydrogen atom, a C 1 -C 40 substituted or unsubstituted alkyl group, a C 2 -C 40 substituted or unsubstituted alkenyl group, a C 2 -C 40 substituted or unsubstituted alkynyl group, a C 6 -C 40 substituted or unsubstituted aryl group, a C 3 -C 40 substituted or unsubstituted heteroaryl group, a C 1 -C 40 substituted or unsubstituted alkoxy group or a C 6 -C 40 substituted or unsubstituted aryloxy group. In the formula (S), R a and R b are independently a C 6 -C 40 substituted or unsubstituted aryl group or a C 1 -C 40 substituted or unsubstituted alkyl group; and R a and R b may combine with each other to form a ring.

  由以下公式（A）表示的二苯并芴烯化合物。在该公式中，R1至R14中至少有一个是由以下公式（S）表示的氨基团；不是由公式（S）表示的R1至R14中的氨基团独立地是氢原子，C1-C40取代或未取代的烷基团，C2-C40取代或未取代的烯基团，C2-C40取代或未取代的炔基团，C6-C40取代或未取代的芳基团，C3-C40取代或未取代的杂芳基团，C1-C40取代或未取代的烷氧基或C6-C40取代或未取代的芳氧基。在公式（S）中，Ra和Rb独立地是C6-C40取代或未取代的芳基团或C1-C40取代或未取代的烷基团；而Ra和Rb可以结合在一起形成环。
• [EN] NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS NUCLÉOTIDIQUES ET LEURS MÉTHODES D'UTILISATION
  申请人：UNIV COLUMBIA

  公开号：WO2017205336A1

  公开（公告）日：2017-11-30

  Disclosed herein, inter alia, are compounds, compositions, and methods of thereof in the sequencing a nucleic acid.

  本公开的内容包括化合物、组合物以及在核酸测序中的方法。
• [EN] P53 MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE p53 ET UTILISATIONS DE CEUX-CI
  申请人：UNIV CALIFORNIA

  公开号：WO2021087096A1

  公开（公告）日：2021-05-06

  Described herein, inter alia, are p53 modulator compounds and methods of using the same. In an aspect is provided a p53 protein covalently bonded to a compound described herein. In an aspect is provided a pharmaceutical composition including a compound described herein and a pharmaceutically acceptable excipient. In an aspect is provided a method of treating cancer in a subject in need of such treatment, including administering to the subject an effective amount of a compound described herein.

  本文描述了p53调节剂化合物及其使用方法等内容。在一个方面，提供了一种p53蛋白与本文描述的化合物共价结合的方法。在一个方面，提供了一种包含本文描述的化合物和药用辅料的药物组合物。在一个方面，提供了一种治疗需要此类治疗的受试者的癌症的方法，包括向受试者施用本文描述的化合物的有效量。